注意欠如多動性障害の市場規模、シェア、動向分析レポート：薬物タイプ別（刺激剤、非刺激剤）、人口統計別（子供、大人）、流通チャネル別、地域別、セグメント予測、2023年～2030年

注意欠如多動性障害市場の成長・動向

Grand View Research, Inc.の最新レポートによると、注意欠如多動性障害の世界市場規模は2030年までに186億9000万米ドルに達すると予測されています。2023年から2030年にかけて、CAGR4.2%で市場が拡大すると予測されています。ADHD治療用の強力な製品パイプラインの存在とその後の承認が、市場の成長を後押しすると予想されます。後期段階のパイプラインには、Neurocentria, Inc.が開発したNRCT-101、Supernus Pharmaceuticals, Inc.のSPN-812、Otsuka America Pharmaceutical, Inc.のEB-1020などが含まれます。

ADHDの早期診断と治療に関して政府機関が行っているいくつかの取り組みが、市場の成長を支えていると思われます。2021年1月、オーストラリア政府は、ADHDの成人患者の治療用としてVyvanseを医薬品給付制度（PBS）に組み入れました。この組み入れにより、Vyvanseを患者に補助金付きで提供できるようになり、2万人以上の患者が低コストで同疾患の同等の治療を受け、利益を得ることができるようになりました。PBSの助成がなければ、患者さんは1人当たり年間1,200米ドル以上の治療費を支払わなければなりませんでした。PBSに組み込まれた後は、1台あたり41.30米ドルで治療が受けられることになります。このような取り組みも、市場の成長を後押しするものと期待されています。

患者、医師、その他の医療従事者の間でADHDに対する認識が高まることで、診断と治療の需要が高まり、注意欠如多動性障害市場の成長を促進する可能性があります。注意欠如多動性障害コーチ機構（ACO）は、認知度を高め、研究開発のための資金を生み出し、障害について人々を教育することを意図したADHDの意識月間として10月を祝います。この取り組みにより、早期診断が促進され、製品の普及が進むと考えられます。

しかし、ADHDの子どもたちは他の精神疾患と併存するリスクが高く、診断や治療が複雑化することが少なくありません。2021年にルンドベック財団が発表した調査結果によると、他の精神疾患が併存しているADHDの患者さんは、薬の服用を避ける傾向が強いことが分かっています。ADHD小児患者さんに典型的に見られる併存疾患には、うつ病、不安症、双極性障害、学習障害、早期言語・コミュニケーション障害、反抗課題性障害などがあります。

さらに、ADHDを治療するための刺激剤の不足により、患者は高価なブランド薬の支払いを余儀なくされ、行動療法などの代替療法の余地が生まれ、ADHDの薬理療法の需要にマイナスの影響を与えることになります。米国麻薬取締局（DEA）などの規制機関により、誤用や乱用を避けるためにADHD治療薬の生産が制限されるなど、厳しい規制が実施されています。需要が増加する中、医療用医薬品の不足が生じ、結果的に治療費が増加し、市場の成長が抑制される可能性があります。このように、医薬品の不足は市場の成長を阻害する可能性があります。

注意欠如多動性障害市場のレポートハイライト

薬剤の種類別では、これらの医薬品と症状の管理に対する高い需要、刺激剤医薬品の使用に対する政府の支援、注意欠如多動性障害に関する臨床試験の継続により、刺激剤セグメントが2022年の市場で最大のシェアを占めている

人口統計学に基づくと、対象人口が多く、注意欠如多動性障害を発症するリスクが高いことから、2022年の注意欠如多動性障害市場は成人セグメントが支配的でした。ADD Health and Wellness Centers, Inc.によると、同障害は成人人口の約4～5%が罹患するとされている

2022年の注意欠如多動性障害市場は、小売薬局セグメントが支配的であり、予測期間中に最も速い成長を示すと予想されます。これは、注意欠如多動性障害治療薬が小売薬局で広く入手可能であり、患者が利用しやすいことに起因しています。

北米は、治療のために利用可能な薬剤に関する医療従事者の高い認知度や疾患有病率の上昇などの要因により、2022年の世界市場を独占しました。カナダADHD啓発センター（CADDAC）によると、カナダでは150万人以上が同疾患に罹患している

アジア太平洋地域は、予測期間中、ADHDの有病率と治療需要の増加により、最も急速に成長する地域となることが予想されます。例えば、ADHDは最も一般的な神経発達疾患の1つであり、オーストラリアでは小児の約8.2％、男児の約11％が診断されています。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • セグメントの範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース：
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ：商品フローアプローチ
• 調査の仮定
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合のスナップショット

第3章 注意欠如多動性障害：市場変数、動向、および範囲

• 市場系列の見通し
  • 中枢神経系治療薬市場
• 浸透と成長の見通しのマッピング
• 規制状況
• 市場力学
• 市場促進要因分析
  • ADHDの有病率の増加
  • 医師と患者の間でADHDについての認識を高める
• 市場抑制要因分析
  • ADHD治療薬の不足
  • 非刺激性ADHD薬の入手可能性が低い
  • 小児の過小診断につながる併存疾患
• PESTEL分析
• 業界分析- ポーターの5つの力
• パイプライン分析

第4章 注意欠陥多動性障害市場：セグメント分析、薬剤タイプ別、2018年～2030年（百万米ドル）

• 注意欠如多動性障害市場：薬物タイプの変動分析
• 覚せい剤系
  • アンフェタミン
  • メチルフェニデート
  • リスデキサンフェタミン
  • デクスメチルフェニデート
• 非覚せい剤系
  • アトモキセチン
  • グアンファシン
  • クロニジン
  • その他

第5章 注意欠如多動性障害市場：セグメント分析、人口統計別、2018年から2030年（百万米ドル）

• 注意欠如多動性障害市場：人口変動分析
• 子供
• 大人

第6章 注意欠如多動性障害市場：セグメント分析、流通チャネル別、2018年から2030年（百万米ドル）

• 注意欠陥・多動性障害市場：流通チャネル変動分析
• 小売薬局
• 病院薬局

第7章 注意欠如多動性障害市場：セグメント分析、地域別、2018年から2030年（百万米ドル）

• 地域市場のスナップショット
• 地域市場シェア分析、2022年および2030年
• 市場規模、予測、および収益とトレンドの分析、2022年から2030年
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 注意欠如多動性障害市場：競合分析

• 主要な市場参入企業別最近の動向と影響分析
  • 相乗効果分析：主要取引と戦略的提携
    • 新製品の発売
    • 合併と買収
    • ライセンシング契約
• 会社の分類
  • イノベーター
  • 市場のリーダー
  • 新興プレーヤー
  • ヒートマップ分析
• 会社の市況分析
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 潜在的なエンドユーザーのリスト
  • 主要企業の市場シェア分析、2022年
  • 消費者行動分析
  • 競合ダッシュボード分析
• 非公開会社
  • 主要新興企業一覧
  • 地域ネットワークマップ
• 企業プロファイル
  • Pfizer, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Johnson &Johnson Services, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Lupin
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Novartis AG
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Takeda Pharmaceutical Company Limited
    • 会社概要
    • シャイア社
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Mallinckrodt plc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • Purdue Pharma Lp
    • 会社概要
    • 製品のベンチマーク
  • NEOS Therapeutics, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発
  • Supernus Pharmaceuticals, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 最近の開発

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 FDA-approved Amphetamine Drugs for ADHD
• Table 5 5 FDA-approved Methylphenidate Drugs for ADHD
• Table 6 FDA-Approved Non-Stimulants Drugs for ADHD
• Table 7 Wholesale Prices of Prescription ADHD Medications
• Table 8 List of Parameters
• Table 9 List of Distributors
• Table 10 Global Attention Deficit Hyperactivity Disorder Market, By Region, 2018 - 2030 (USD Million)
• Table 11 Global Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 12 Global Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 13 Global Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 14 North America Attention Deficit Hyperactivity Disorder Market, By Country, 2018 - 2030 (USD Million)
• Table 15 North America Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 16 North America Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 17 North America Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 U.S. Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 19 U.S. Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 20 U.S. Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Canada Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 22 Canada Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 23 Canada Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 Europe Attention Deficit Hyperactivity Disorder Market, By Country, 2018 - 2030 (USD Million)
• Table 25 Europe Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 26 Europe Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 27 Europe Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Germany Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 29 Germany Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 30 Germany Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 UK Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 32 UK Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 33 UK Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 France Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 35 France Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 36 France Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Italy Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 38 Italy Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 39 Italy Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Spain Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 41 Spain Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 42 Spain Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Attention Deficit Hyperactivity Disorder Market, By Country, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Japan Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 48 Japan Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 49 Japan Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 China Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 51 China Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 52 China Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 India Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 54 India Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 55 India Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 South Korea Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 57 South Korea Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 58 South Korea Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 Australia Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 60 Australia Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 61 Australia Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Latin America Attention Deficit Hyperactivity Disorder Market, By Country, 2018 - 2030 (USD Million)
• Table 63 Latin America Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 64 Latin America Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 65 Latin America Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Brazil Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 67 Brazil Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 68 Brazil Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Mexico Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 70 Mexico Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 71 Mexico Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 Argentina Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 73 Argentina Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 74 Argentina Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 Middle East & Africa Attention Deficit Hyperactivity Disorder Market, By Country, 2018 - 2030 (USD Million)
• Table 76 Middle East & Africa Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 77 Middle East & Africa Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 78 Middle East & Africa Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 80 Saudi Arabia Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 82 South Africa Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 83 South Africa Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 85 UAE Attention Deficit Hyperactivity Disorder Market, By Demographics, 2018 - 2030 (USD Million)
• Table 86 UAE Attention Deficit Hyperactivity Disorder Market, By Drug Type, 2018 - 2030 (USD Million)
• Table 87 UAE Attention Deficit Hyperactivity Disorder Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Attention Deficit Hyperactivity Disorder (ADHD) Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Information Procurement
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value Chain-based Sizing & Forecasting
• Fig. 7 QFD Modeling for Market Share Assessment
• Fig. 8 Market Formulation & Validation
• Fig. 9 Commodity Flow Approach
• Fig. 10 Market Snapshot (2022) (USD Million)
• Fig. 11 Segment Snapshot (2022) (USD Million)
• Fig. 12 Competitive Snapshot
• Fig. 13 Penetration & Growth Prospect Mapping
• Fig. 14 ADHD Market Driver Impact
• Fig. 15 ADHD Market Restraint Impact
• Fig. 16 PESTEL Analysis
• Fig. 17 Porter's Five Forces Analysis
• Fig. 18 Attention Deficit Hyperactivity Disorder (ADHD) Drug Type Outlook: Key Takeaways
• Fig. 19 Attention Deficit Hyperactivity Disorder Market: Drug Type Movement Analysis (USD Million)
• Fig. 20 Stimulants Market 2018 - 2030 (USD Million)
• Fig. 21 Amphetamine Market, 2018 - 2030 (USD Million)
• Fig. 22 Methylphenidate Market, 2018 - 2030 (USD Million)
• Fig. 23 Lisdexamfetamine Market, 2018 - 2030 (USD Million)
• Fig. 24 Dexmethylphenidate Market, 2018 - 2030 (USD Million)
• Fig. 25 Non - stimulants Market, 2018 - 2030 (USD Million)
• Fig. 26 Atomoxetine Market, 2018 - 2030 (USD Million)
• Fig. 27 Guanfacine Market, 2018 - 2030 (USD Million)
• Fig. 28 Clonidine Market, 2018 - 2030 (USD Million)
• Fig. 29 Others Market, 2018 - 2030 (USD Million)
• Fig. 30 Attention Deficit Hyperactivity Disorder Demographic Outlook: Key Takeaways
• Fig. 31 Attention Deficit Hyperactivity Disorder Market: Demographic Movement Analysis (USD Million)
• Fig. 32 Children (2 - 17 years) Market, 2018 - 2030 (USD Million)
• Fig. 33 Adult Market, 2018 - 2030 (USD Million)
• Fig. 34 Attention Deficit Hyperactivity Disorder Distribution Channel Outlook: Key Takeaways
• Fig. 35 Attention Deficit Hyperactivity Disorder Market: Distribution Channel Analysis (USD Million)
• Fig. 36 Retail Pharmacy Market, 2018 - 2030 (USD Million)
• Fig. 37 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• Fig. 38 Regional Snapshot, 2022 & 2030
• Fig. 39 Regional Market Place: Key takeaways
• Fig. 40 North America
• Fig. 41 North America Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD million)
• Fig. 42 U.S.
• Fig. 43 U.S. Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 44 Canada
• Fig. 45 Canada Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD million)
• Fig. 46 Europe
• Fig. 47 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 48 U.K.
• Fig. 49 U.K. Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 50 Germany
• Fig. 51 Germany Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 52 Spain
• Fig. 53 Spain Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 54 France
• Fig. 55 France Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 56 Italy
• Fig. 57 Italy Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 58 Asia Pacific
• Fig. 59 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 60 Japan
• Fig. 61 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 62 China
• Fig. 63 China Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 64 India
• Fig. 65 India Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 66 Australia
• Fig. 67 Australia Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 68 South Korea
• Fig. 69 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 70 Latin America
• Fig. 71 Latin America Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 72 Brazil
• Fig. 73 Brazil Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 74 Mexico
• Fig. 75 Mexico Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 76 Argentina
• Fig. 77 Argentina Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 78 Middle East & Africa
• Fig. 79 MEA Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 80 South Africa
• Fig. 81 South Africa Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 82 Saudi Arabia
• Fig. 83 Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 84 UAE
• Fig. 85 UAE Attention Deficit Hyperactivity Disorder (ADHD) Market, 2018 - 2030 (USD Million)
• Fig. 86 Heat Map Analysis
• Fig. 87 Company Market Position Analysis, 2022
• Fig. 88 Company Market Position Analysis, 2022
• Fig. 89 Company Market Share Analysis (2022)
• Fig. 90 Consumer Behavior Analysis
• Fig. 91 Market Differentiators

Attention Deficit Hyperactivity Disorder Market Growth & Trends:

The global attention deficit hyperactivity disorder market size is expected to reach USD 18.69 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.2% from 2023 to 2030. The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.

Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.

Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.

However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.

Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.

Attention Deficit Hyperactivity Disorder Market Report Highlights:

• By drug type, the stimulants segment accounted for the largest share of the market in 2022 due to the high demand for these medicines and the management of symptoms, government support for the use of stimulants drugs, and continuing clinical trials regarding attention deficit hyperactive disorder

• Based on demographics, the adults segment dominated the attention-deficit hyperactivity disorder market in 2022 owing to the large target population base and high risk of developing the attention-deficit hyperactive disorder. According to ADD Health and Wellness Centers, Inc. the disorder affects approximately 4-5% of the adult population

• Retail pharmacy segment dominated the attention-deficit hyperactivity disorder market in 2022 and is anticipated to witness the fastest growth over the forecast period. This can be attributed to the wide availability of attention deficit hyperactivity disorder drugs at retail pharmacies and their ease of accessibility to patients

• North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence. According to the Center for ADHD Awareness Canada (CADDAC), more than 1.5 million people are affected by the disease in Canada

• Asia Pacific is expected to be the fastest-growing region during the forecast period to increasing ADHD prevalence and treatment demand in the region. For instance, ADHD is one of the most common neurodevelopment diseases with approximately 8.2% of children and 11% of boys diagnosed in Australia

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment scope
  • 1.1.2 Regional scope
  • 1.1.3 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database:
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation and Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Snapshot

Chapter 3 Attention Deficit Hyperactivity Disorder: Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Central Nervous System Therapeutics Market
• 3.2 Penetration and Growth Prospect Mapping
• 3.3 Regulatory Landscape
• 3.4 Market Dynamics
• 3.5 Market Driver Analysis
  • 3.5.1 Increasing Prevalence of ADHD
  • 3.5.2 Increasing Awareness About ADHD Among Physicians and Patients
• 3.6 Market Restraint Analysis
  • 3.6.1 Shortage of ADHD Drugs
  • 3.6.2 Low Availability of Non-stimulant ADHD Drugs
  • 3.6.3 Comorbidities Leading to Underdiagnosis in Children
• 3.7 PESTEL Analysis
• 3.8 Industry Analysis - Porter's Five Forces
• 3.9 Pipeline Analysis

Chapter 4 Attention Deficit Hyperactivity Disorder Market: Segment Analysis, by Drug Type, 2018 - 2030 (USD Million)

• 4.1 Attention Deficit Hyperactivity Disorder Market: Drug Type Movement Analysis
• 4.2 Stimulants
  • 4.2.1 Stimulants Market, 2018 - 2030 (USD Million)
  • 4.2.2 Amphetamine
    • 4.2.2.1 Amphetamine Market, 2018 - 2030 (USD Million)
  • 4.2.3 Methylphenidate
    • 4.2.3.1 Methylphenidate Market, 2018 - 2030 (USD Million)
  • 4.2.4 Lisdexamfetamine
    • 4.2.4.1 Lisdexamfetamine Market, 2018 - 2030 (USD Million)
  • 4.2.5 Dexmethylphenidate
    • 4.2.5.1 Dexmethylphenidate Market, 2018 - 2030 (USD Million)
• 4.3 Non - Stimulants
  • 4.3.1 Non - stimulants Market, 2018 - 2030 (USD Million)
  • 4.3.2 Atomoxetine
    • 4.3.2.1 Atomoxetine Market, 2018 - 2030 (USD Million)
  • 4.3.3 Guanfacine
    • 4.3.3.1 Guanfacine Market, 2018 - 2030 (USD Million)
  • 4.3.4 Clonidine
    • 4.3.4.1 Clonidine Market, 2018 - 2030 (USD Million)
  • 4.3.5 Others
    • 4.3.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Attention Deficit Hyperactivity Disorder Market: Segment Analysis, by Demographic, 2018 - 2030 (USD Million)

• 5.1 Attention Deficit Hyperactivity Disorder Market: Demographics Movement Analysis
• 5.2 Children
  • 5.2.1 Children Market, 2018 - 2030 (USD Million)
• 5.3 Adults
  • 5.3.1 Adult Market, 2018 - 2030 (USD Million)

Chapter 6 Attention Deficit Hyperactivity Disorder Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Attention Deficit Hyperactivity Disorder Market: Distribution Channel Movement Analysis
• 6.2 Retail Pharmacy
  • 6.2.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 6.3 Hospital Pharmacy
  • 6.3.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7 Attention Deficit Hyperactivity Disorder Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 7.1 Regional Market Snapshot
• 7.2 Regional Market Share Analysis, 2022 & 2030
• 7.3 Market Size, Forecasts, and Revenue & Trend Analysis, 2022 to 2030
  • 7.3.1 North America
    • 7.3.1.1 North America Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.1.2 U.S.
    • 7.3.1.2.1 U.S. Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.1.3 Canada
    • 7.3.1.3.1 Canada Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.3.2 Europe
    • 7.3.2.1 Europe Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.2 UK
    • 7.3.2.2.1 UK Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.3 Germany
    • 7.3.2.3.1 Germany Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.4 Spain
    • 7.3.2.4.1 Spain Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.5 France
    • 7.3.2.5.1 France Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.6 Italy
    • 7.3.2.6.1 Italy Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.3.3 Asia Pacific
    • 7.3.3.1 Asia Pacific Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.2 Japan
    • 7.3.3.2.1 Japan Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.3 China
    • 7.3.3.3.1 China Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.4 India
    • 7.3.3.4.1 India Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.5 Australia
    • 7.3.3.5.1 Australia Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.6 South Korea
    • 7.3.3.6.1 South Korea Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.3.4 Latin America
    • 7.3.4.1 Latin America Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.2 Brazil
    • 7.3.4.2.1 Brazil Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.3 Mexico
    • 7.3.4.3.1 Mexico Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.4 Argentina
    • 7.3.4.4.1 Argentina Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.3.5 MEA
    • 7.3.5.1 MEA Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.2 South Africa
    • 7.3.5.2.1 South Africa Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.3 Saudi Arabia
    • 7.3.5.3.1 Saudi Arabia Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.4 UAE
    • 7.3.5.4.1 UAE Attention Deficit Hyperactivity Disorder Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8 Attention Deficit Hyperactivity Disorder Market: Competitive Analysis

• 8.1 Recent Developments and Impact Analysis, by Key Market Participants
  • 8.1.1 Synergy Analysis: Major Deals and Strategic Alliances
    • 8.1.1.1 New Product Launches
    • 8.1.1.2 Mergers and Acquisitions
    • 8.1.1.3 Licensing Agreements
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
  • 8.2.3 Emerging Players
  • 8.2.4 Heat Map Analysis
• 8.3 Company Market Position Analysis
• 8.4 Vendor Landscape
  • 8.4.1 List of Key Distributors and Channel Partners
  • 8.4.2 List of Potential End-Users
  • 8.4.3 Key Company Market Share Analysis, 2022
  • 8.4.4 Consumer Behavior Analysis
  • 8.4.5 Competitive Dashboard Analysis
• 8.5 Private Companies
  • 8.5.1 List of Key Emerging Companies
  • 8.5.2 Regional Network Map
• 8.6 Company Profiles
  • 8.6.1 Pfizer, Inc.
    • 8.6.1.1 Company Overview
    • 8.6.1.2 Financial Performance
    • 8.6.1.3 Product Benchmarking
    • 8.6.1.4 Recent Developments
  • 8.6.2 Johnson & Johnson Services, Inc.
    • 8.6.2.1 Company Overview
    • 8.6.2.2 Financial Performance
    • 8.6.2.3 Product Benchmarking
    • 8.6.2.4 Recent Developments
  • 8.6.3 Lupin
    • 8.6.3.1 Company Overview
    • 8.6.3.2 Financial Performance
    • 8.6.3.3 Product Benchmarking
    • 8.6.3.4 Recent Developments
  • 8.6.4 Novartis AG
    • 8.6.4.1 Company Overview
    • 8.6.4.2 Financial Performance
    • 8.6.4.3 Product Benchmarking
    • 8.6.4.4 Recent Developments
  • 8.6.5 Takeda Pharmaceutical Company Limited
    • 8.6.5.1 Company Overview
    • 8.6.5.2 Shire plc
    • 8.6.5.3 Financial Performance
    • 8.6.5.4 Product Benchmarking
    • 8.6.5.5 Recent Developments
  • 8.6.6 Mallinckrodt plc.
    • 8.6.6.1 Company Overview
    • 8.6.6.2 Financial Performance
    • 8.6.6.3 Product Benchmarking
  • 8.6.7 Purdue Pharma L.p.
    • 8.6.7.1 Company Overview
    • 8.6.7.2 Product Benchmarking
  • 8.6.8 NEOS Therapeutics, Inc.
    • 8.6.8.1 Company Overview
    • 8.6.8.2 Financial performance
    • 8.6.8.3 Product Benchmarking
    • 8.6.8.4 Recent Developments
  • 8.6.9 Supernus Pharmaceuticals, Inc.
    • 8.6.9.1 Company Overview
    • 8.6.9.2 Financial performance
    • 8.6.9.3 Product Benchmarking
    • 8.6.9.4 Recent Developments